Immunocore Holdings (IMCR) Income from Continuing Operations (2023 - 2026)

Immunocore Holdings has disclosed Income from Continuing Operations across 4 years of filings, most recently posting 12972000.0 for Q1 2026.

• Income from Continuing Operations for Q1 2026 came in at 12972000.0, up 160.27% year-over-year; the trailing twelve-month figure through Mar 2026 was 27607000.0 (down 27.08% YoY), and the FY2025 annual result was 35514000.0, up 30.48% from the prior year.
• Income from Continuing Operations came in at 12972000.0 for Q1 2026 at Immunocore Holdings, up from 30108000.0 in the prior quarter.
• In the past five years, Income from Continuing Operations ranged from a high of 12972000.0 in Q1 2026 to a low of 30108000.0 in Q4 2025.
• The 4-year median for Income from Continuing Operations is 11630000.0 (2024), against an average of 9927230.77.
• Across the five-year window, Income from Continuing Operations soared 859.49% in 2024 and plunged 102.04% in 2025, its largest moves.
• Immunocore Holdings' Income from Continuing Operations stood at 19730000.0 in 2023, then dropped by 20.48% to 23771000.0 in 2024, then dropped by 26.66% to 30108000.0 in 2025, then surged by 143.08% to 12972000.0 in 2026.
• The last three Income from Continuing Operations figures came in at 12972000.0 (Q1 2026), 30108000.0 (Q4 2025), and 177000.0 (Q3 2025), per Business Quant data.